Kevin Anderson
About Kevin Anderson
Kevin Anderson serves as the Sr. Director of Clinical Operations at AlloVir, where he oversees clinical studies related to allogeneic stem cell transplants and kidney transplants. He has extensive experience in clinical operations, having held various leadership roles in notable pharmaceutical companies over the past two decades.
Work at AlloVir
Kevin Anderson has served as Sr. Director of Clinical Operations at AlloVir since 2022. In this role, he oversees Clinical Operations, Data Management, and Pharmacovigilance. He manages a team of six professionals and has been instrumental in closing various operational aspects. Anderson has led GDPR activities and has overseen three Phase 3 studies, two Phase 2 studies, and a patient registry focusing on viruses associated with allogeneic stem cell transplants and kidney transplants.
Previous Experience in Clinical Operations
Prior to joining AlloVir, Kevin Anderson held several significant positions in clinical operations. He worked at PTC Therapeutics, Inc. as Sr. Director of Clinical Operations from 2021 to 2022. Before that, he was Director of Global Clinical Operations at Alexion Pharmaceuticals, Inc. from 2017 to 2021. His earlier roles include Clinical Trial Manager at Biogen, Clinical Project Manager at CR Bard, and Sr. Clinical Project Manager at Shire. He began his career at Amgen, where he progressed through the ranks from Clinical Research Associate I to III.
Education and Expertise
Kevin Anderson holds a Master of Business Administration (MBA) from Boston College Carroll School of Management. He also earned a Bachelor of Arts in Psychology from Eastern University. His educational background complements his extensive experience in overseeing operational facets of clinical studies, from early phase to registrational studies. Anderson has spearheaded numerous agency inspections and BLA submissions throughout his career.
Achievements in Clinical Research
Throughout his career, Kevin Anderson has achieved significant milestones in clinical research. He has overseen multiple clinical studies, including three Phase 3 studies and two Phase 2 studies. His leadership in Pharmacovigilance activities lasted for nine months, contributing to the safety monitoring of clinical trials. Anderson's experience includes managing complex projects and ensuring compliance with regulatory standards.